Northern Trust Corp Acquires 12,517 Shares of ANI Pharmaceuticals, Inc. $ANIP

Northern Trust Corp raised its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 6.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 216,862 shares of the specialty pharmaceutical company’s stock after purchasing an additional 12,517 shares during the period. Northern Trust Corp owned 1.00% of ANI Pharmaceuticals worth $14,519,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. National Bank of Canada FI purchased a new position in ANI Pharmaceuticals in the 1st quarter valued at approximately $79,000. GAMMA Investing LLC boosted its holdings in shares of ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock worth $95,000 after acquiring an additional 881 shares during the period. Rafferty Asset Management LLC purchased a new position in shares of ANI Pharmaceuticals in the fourth quarter valued at $200,000. Bridgefront Capital LLC bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at $204,000. Finally, Mesirow Financial Investment Management Inc. bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at $206,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $94.92 on Thursday. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $95.60. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. The stock has a market cap of $2.06 billion, a P/E ratio of -123.27 and a beta of 0.63. The firm’s fifty day moving average price is $75.06 and its 200-day moving average price is $67.74.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The business had revenue of $211.37 million for the quarter, compared to analysts’ expectations of $187.18 million. During the same quarter in the prior year, the firm earned $1.02 earnings per share. The firm’s revenue was up 53.2% on a year-over-year basis. On average, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ANIP has been the subject of a number of recent analyst reports. Truist Financial lifted their target price on ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a “hold” rating in a report on Monday, August 11th. Piper Sandler restated an “overweight” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. Guggenheim reissued a “buy” rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Finally, HC Wainwright restated a “buy” rating and set a $93.00 price target (up from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $84.75.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 52,990 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $87.15, for a total transaction of $4,618,078.50. Following the transaction, the chief operating officer directly owned 531,920 shares of the company’s stock, valued at approximately $46,356,828. This trade represents a 9.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeanne Thoma sold 21,540 shares of the company’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $89.15, for a total transaction of $1,920,291.00. Following the completion of the sale, the director directly owned 23,405 shares of the company’s stock, valued at $2,086,555.75. This trade represents a 47.93% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 405,538 shares of company stock worth $35,690,131 in the last quarter. 12.70% of the stock is owned by company insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.